HLVX — HilleVax Income Statement
0.000.00%
Last trade - 00:00HealthcareMid Cap
- $652.66m
- $433.45m
Annual income statement for HilleVax, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 0.633 | 1.29 | 53.4 | 65.1 |
| Operating Profit | -0.633 | -1.29 | -53.4 | -65.1 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -0.673 | -2.1 | -102 | -160 |
| Net Income After Taxes | -0.673 | -2.1 | -102 | -160 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.673 | -2.1 | -102 | -160 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.673 | -2.1 | -102 | -160 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.021 | -0.066 | -3.23 | -5.89 |
| Dividends per Share |